Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

AAA. See abdominal aortic aneurysm ABCD2 Score, 339-40 abdominal aortic aneurysm (AAA), reliability of testing for, 338 with screening tests, 350 absolute risk increase (ARI), 221 - 2absolute risk reduction (ARR), 3, 215-17, 221-2 confidence intervals around, 292 - 3black belt, 295 blue belt, 294 brown belt, 294-5 green belt, 293-4 white belt, 293 vellow belt, 293 accuracy, 8-9, 12, 319-20 in diagnostic test studies, 76-80 reliability in lieu of, 110 of risk predictions calibration in, 147-9, 152-67, 338-9 discrimination in, 146, 150-67, 338-9 NRI and IDI for, 165-6 quantification of, 146-67, 338-9 recalibration and, 154 acetaminophen (Tylenol[®]), 355-6 ACI-TIPI. See Acute Coronary Ischemia-Time Insensitive Predictive Instrument acute cardiac ischemia, wall motion abnormalities as test for, 80, 329 Acute Coronary Ischemia-Time Insensitive Predictive Instrument (ACI-TIPI), 192 - 3acute ligamentous knee injury, 2 ADHD. See attention deficithyperactivity disorder

adjustment from anchor, in probability estimates, 310-11 Advair[®] inhaler, 216–17 age at first birth, college education and, 349 ALND. See axillary lymph node dissection α, 281 Altman, Douglas, 290 ambiguous test results, spectrum bias from exclusion of, 86-97 American Cancer Society, 305-6 amoxicillin for bacteremia in newborns, 292 - 5for OME, 344-5 amylase, serum, 78-80 anchoring bias, 311-12 anticholinergic medication, for enuresis, 345-6 antidepressants prenatal, 354-5 randomized trials with, confidence intervals in, 353 - 4appendicitis partial verification bias and, 83 reliability of testing for, 333 speed bumps as diagnostic tool for, 332 WBC count for, 313 area under an ROC curve (AUROC), 51 discrimination in risk predictions and, 150-67 Wilcoxon Rank Sum test and, 54-5 ARI. See absolute risk increase ARR. See absolute risk reduction ASD. See autism spectrum disorder as-treated analysis, 211-13 attention deficit-hyperactivity disorder (ADHD), 348

AUROC. See area under an ROC curve AUSTRI trial, 216-17 authors, of randomized trials, 206 autism spectrum disorder (ASD), 354-5 autonomy, clinician, 306-7 availability, in probability estimates, 310 average standard deviation, 123 axillary lymph node dissection (ALND), 79-80, 318-56 B. See cost of failing to treat bacteremia classification trees for, 183, 185 in newborn, 5, 47-8 confidence intervals in negative studies of, 292-5 posterior probability for multi-level tests of, 60 regret graphs for, 63-4 ROC curve and, 48-51, 55 bacterial meningitis bias in diagnostic test studies of, 330 classification trees for, 183, 185 ROC curve and, 51-2 base-rate neglect, 309, 311-12 Bayes, Thomas, 3 Bayesian statistical analysis. See also posterior probability; prior probability of clinical trials, 291-2 confidence intervals and, 290 P-values and, 282-4 benefit per bad outcome prevented (BBOP), 218-21 β , 281 between-group comparisons, in randomized trials, 214 bias anchoring, 311-12 cognitive, 311

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

bias (cont.) confirmation, 311 in diagnostic test studies, 78 application of, 100-1 differential verification. 81-2, 86-8, 329-30 double gold standard, 81-2, 86-8, 329-30 imperfect gold standard, 81-2, 89-91, 330-2 incorporation, 78-82, 329 partial verification, 80-5, 330 spectrum, 81-2, 86-97, 330 falsification tests for, 236-8, 348 immortal time, 242, 349 mean, 147-9, 338-9 in post-test probability estimates, 311-13 in pre-test probability estimates, 309-11 publication, 161-2 in randomized trials, 215 in screening test studies, 258 - 68lead-time, 260-1 length-time, 261-2 pseudodisease, 263-6 slippery linkage, 267-8 stage migration, 261-3, 353 sticky diagnosis, 258-68 volunteer effect, 259-60 spectrum in bacterial meningitis findings, 330 definition of, 81-2, 91-3 disease definition v., 93-5 disease prevalence and, 94-5 ESR and, 92-3 exclusion of intermediate test results and, 86-97 sensitivity in, 81-2, 91-3 specificity in, 81-2, 91-3 tests nonindependence and, 177-8 bilirubin, partial verification bias and, 83-5 Bland-Altman plot, 128-9, 338 modified, 127-30 variable types and, for reliability, 110-11

blinding, in randomized trials, 208-9, 345 blue belts, 294 BMD. See bone mineral density BNP. See B-type natriuretic peptide body packing, reliability of testing for, 333-8 bone mineral density (BMD), test-retest reliability in, 127 - 9Bonferroni correction, 287-9 in antidepressant randomized trials, 353 - 4bootstrap aggregation, 196 branch, of classification trees, 181 - 2BRCA testing, referral screening tool for, 321-39 breast cancer, 5, 269-70 ALND for staging of, 79-80, 318-56 BRCA referral screening tool for, 321-39 EBM and screening of, 304-6 likelihood ratios applied to, 16-17, 21 risk prediction studies for, 163 stage migration bias and, 262 - 32×2 table method applied to, 15 - 16breast development, reliability of staging of, 131 unbalanced disagreement and, 116 weighted kappa for, 118-20 Brier Score, 147-9, 338-9 brown belt, 294-5 Browner, Warren, 285 B-type natriuretic peptide (BNP), 58-9, 80 C. See cost of treating nondisease CACE. See Complier Average Causal Effect

Calibrated Finger Rub Auditory Screening Test (CALFRAST), 327–8 calibration, 127–30 in risk predictions, 146–9

for ICU Mortality Probability Model, 153-67 for low back pain, 152 mean bias, MAE, and Brier Score for, 147-9, 338-9 recalibration and, 154 ROC curves compared with plots of, 151-67 cancer screening tests differential verification bias in. 86 in EBM, 304-6 overdiagnosis in, 263-5 total v. cause-specific mortality in, 266-9 cannabinoid hyperemesis syndrome, 308 Cardiac Arrhythmia Suppression Trial, 252 cardiovascular disease risk predictions for, 341-2 vitamin E for prevention of, 231-2, 237 case-control sampling, 12-14, 321 in diagnostic test studies, 75 - 7categorical variables disease definition and, 93-5 inter-observer agreement for, 111-21, 332-8 category-free NRI, 165-6 cause-specific mortality, total mortality v., 266-9 CBOP. See cost per bad outcome prevented CDC. See US Centers for Disease Control ceftriaxone, for post Lyme syndrome, randomized trials of, 345 CHD. See congenital heart disease chest pain classification trees for, 183-4 reliability of testing for, 333-4 chest wall motion, as test for acute cardiac ischemia, 80, 329 chest x-ray, for lung cancer screening, 350-1 CHF. See congestive heart failure

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

chorionic villus sampling (CVS), 5, 93-5, 178-83, 186, 189-91 chromosomal abnormalities, fetal, 5, 93-5, 178-83, 186, 188-91 classification trees, 181-5 clinical decision making, probability estimates v., 312-13 clinical decision rules clinician v., 198 EBM in future, 314-15 k-fold cross validation in, 196 logistic regression in development of, 192-5 overfitting and, 193-6 test selection for, 192-6 clinical experience, statistical expertise v., 304 clinical trials, Bayesian analysis of, 291–2 clinician autonomy of, 306-7 clinical decision rules v., 198 EBM diagnostic errors and, 308-13 CMV. See cytomegalovirus cognitive bias, 311 colic, testing for, 318 college education, age at first birth and, 349 colon cancer, screening tests for, 269-70 community-acquired pneumonia, risk predictions for, 340 comparison group, in randomized trials, 207 Complier Average Causal Effect (CACE), 234 composite endpoints, 209-10 computed tomography (CT), 4 for AAA, reliability of testing for, 338 for body packing, reliability of testing for, 333-8 for lung cancer screening, 350 - 1computed tomography angiography (CTA), spectrum bias in, 93 computed tomography pulmonary angiogram (CTPA), for PE, 60-2, 66, 325-6, 343-4

conclusions, in diagnostic test studies, 76-80 conditional independence in imperfect gold standard bias, 89-90 of tests, 175 conditional probability, 10 confidence intervals, 280 for acetaminophen with vaccines, 355-6 in antidepressant randomized trials, 353 - 4around ARR, 292-3 black belt, 295 blue belt, 294 brown belt, 294-5 green belt, 293-4 white belt, 293 vellow belt, 293 background on classical (frequentist) statistics, 281-2 stochastic and epistemic probability, 280-1 definition of, 289-90 for epidural analgesia and C-section rates, 355 for Grim Reaper walking speed, 354 in prenatal antidepressant and autism studies, 354-5 P-values and, 292-3 in sentinel-node biopsy v. axillary dissection, 356 for small numerators, 295-6 confirmation bias, 311 confounding falsification tests for, 236-8, 348 in observational studies, 231-3 propensity scores for, 238-41, 348-9 randomized trials for minimization of, 205-6 in screening tests, 259-60 confounding by indication, 231 - 3congenital CMV, screening tests for, 353 congenital heart disease (CHD), screening tests for, 353

congestive heart failure (CHF), BNP test in, 58-9, 80 continuous measurements, reliability in, 121 calibration for, 127-30 test-retest, 121 average standard deviation and, 123 correlation coefficient and, 123-5 error by magnitude with, 125 - 7method comparison for, 127 - 9within-subject standard deviation/repeatability, 122-3 continuous outcomes, risk predictions for, 164 continuous test, 47 dichotomous, 47-8 Grim Reaper walking speed, 327 in hypothetical trial cases, 326-7 logistic regression for, 189-91 ROC curves in, 51-2 AUROC and, 51, 54-5 information in, 55 likelihood ratio relationship to, 57-9, 325 - 6optimal cutoffs and, 62-3 in signal detection theory, 49 - 50for urinalysis, 323-5 walking man approach to, 52 - 4for WBC count in joint fluid, 322-3 WBC counts and, 48-51, 55 Wilcoxon Rank Sum test and, 54-5 WBC count, 47-8 continuous variables, 110-11 disease definition and, 93, 330 in randomized trials, 215 cooling, of newborns, 291-2 copper standard. See imperfect gold standard bias coronary artery aneurysms, multiple tests for, 332-42

359

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

correlation coefficient, test-retest reliability and, 123-5 cost of failing to treat disease (B), 23, 34-6 cost of test (T), 23, 34-6 cost of treating nondisease (C), 23, 34-6 cost per bad outcome prevented (CBOP), 218-21 count outcome variables, in randomized trials, 215 critical appraisal of diagnostic test studies, step-by-step approach to, 75-80 of randomized trials, 206 design and conduct, 206-11 results analysis, 211-15 of screening test studies, 257 - 70mortality v. survival in, 258 observational studies, 259-66 randomized trials, 265-9 of studies of prediction, 160 - 3cross-sectional sampling, 9-14, 321 in diagnostic test studies, 75-7 C-section rates, epidural analgesia and confidence intervals in, 355 observational studies of, 244-5, 338-47 CT. See computed tomography CTA. See computed tomography angiography CTPA. See computed tomography pulmonary angiogram custom weights, for weighted kappa statistic, 120-1 cutoffs, 8, 47-8 in classification trees, 183-4 disease definition and, 93, 330 logistic regression and, 189 in multilevel testing, 61-2 D-Dimer, 325-6 graphical approach to, 63 - 4

ROC curves and, 62-3 ROC curves and, 48-52, 62 - 3CVS. See chorionic villus sampling cytomegalovirus (CMV), screening tests for, 353 D+/D-. See dichotomous disease state D-Dimer, 60-2, 66, 325-6, 343-4 decision curves, 156-60 decision making, probability estimates v., 312-13 decision problems, in diagnoses, 4-5 decision rules EBM in future, 314-15 multivariable, 175, 180-1, 192-5 clinician v., 198 k-fold cross validation in, 196 overfitting and, 193-6 test selection for, 192 - 6deep vein thrombosis (DVT), ultrasound diagnosis of, 96 - 7delayed cooling study, Bayesian analysis of, 291-2 depression, paroxetine or imipramine for, randomized trials with, confidence intervals in, 353 - 4derivation sets, 195-6 dermoscopy, for melanoma diagnosis, 332-54 diagnosis, in EBM, 2-3 with CT, 4 D+/D- and, 4 decision problems in, 4-5 errors in, 307-13 purpose of, 1-2 testing in, 4 diagnostic tests, 4 bias in studies of, 78-97, 100-1, 329-32 for breast cancer, 79-80, 318 - 56checklists for, 100-1 for colic, 318 for ectopic pregnancy, studies for, 4

individual patient data meta-analysis of, 99-100 for metastatic undifferentiated carcinoma, 318 P-values and, analogy with, 282 - 6results of, disease probability estimation and, 3 risk predictions v., 144-6 for rotavirus, 318 for sexual abuse, in prepubertal girls, 336-7 step-by-step appraisal of studies of, 75-80 studies for appendicitis diagnosis with speed bumps, 332 bias in, 78-97, 100-1 checklists for, 100-1 conclusions in, 76-80 design for, 75-7, 79-80 gold standard test in, 76-7, 79 - 80index test in, 76-7, 79-80 outcome variables, 76-7, 79-80 predictor variables, 76-7, 79 - 80research questions in, 79-80 results in, 76-80 step-by-step appraisal of, 75-80 subjects in, 75-7, 79-80 systematic reviews of, 98-100, 332-54 dichotomous disease state (D+/D-), 4dichotomous tests accuracy in, 8-9, 12, 319-20 benefit/cost quantification in, 23 continuous, 47-8 cutoffs in, 8, 47-8 ROC curves and, 48-52 definitions of, 8, 31 for Grunderschnauzer disease, 319 likelihood ratios for, 319-20 derivation of, 19-20, 32 posterior probability calculation with, 16-17, 21 slide rule for, 21-2, 25-7

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

multiple logistic regression for, 186 - 7result combination of, 178-81 negative predictive value and, 8-11, 319-21 patient information combined with, 14-15 positive predictive value in, 8-11, 319-21 post-test probability in, 12 - 14pre-test probability in, 11, 13 - 14prevalence in, 9-11 ROC curve for, 51 sampling schemes for, 9-14, 321 sensitivity, 8-10, 320-39 specificity, 8-11, 320-39 for streptococcal infection, 321 - 2treatment and testing thresholds for, 22-40, 321 - 2expected cost of, 23-5 for imperfect and costly test, 29-30, 34-6 for imperfect but costless test, 25-6, 29, 34-6 no treat-test, 25-30, 37-40 for perfect but risky or expensive test, 28-9, 34 - 6test-treat, 25-30, 37-40 treatment threshold probability and, 23-5 visualization of, 25-7 2×2 table method for updating prior probability in, 15-16, 19 - 20blank, 15 completed, 16 dichotomous variables, 110-11 kappa for, 112-13 differential diagnosis, in EBM, 308 differential distance instrument, 234-5 differential verification bias, 81-2, 86-8, 329-30 discrete variables, 110-11

discrimination, in risk predictions, 146, 150, 338-9 for ICU Mortality Probability Model, 153-67 for low back pain, 152 recalibration and, 154 risk ratios, rate ratios, and hazard ratios for, 154 ROC curves and, 150-67 diseases classification systems for, 1 - 2definition of, spectrum bias v., 93-5 dichotomous oversimplification of, 4 heterogeneous, 176 latent phase of, 257 probability estimates for, 2-3, 308-13 screening tests for, 251-2 double gold standard bias, 81-2, 86-8, 329-30 Down syndrome, 5, 93-5, 178-83, 186, 188-91, 344 CHD screening in, 353 dual-energy x-ray absorptiometry (DXA), test-retest reliability in, 127-9 DVT. See deep vein thrombosis DXA. See dual-energy x-ray absorptiometry EBM. See evidence-based medicine echocardiogram, as test for acute cardiac ischemia, 80, 329 ectopic pregnancy, diagnostic testing studies for, 4 elbow extension test, 329-30 enuresis, randomized trials for, 345-6 epidural analgesia, C-section rates and confidence intervals in, 355 observational studies of, 244-5, 338-47 epistemic probability, 280-1 equivalency trials, 215 error, measurement. See measurement error, in testing

errors conditionally independent, in imperfect gold standard bias, 89-90 in EBM diagnostic process, 307 clinician, 308-13 differential diagnosis, 308 oversimplification of diagnostic problem, 313 probability, 308-13 mean absolute, 147-9, 338-9 post-test estimate, 311-13 pre-test estimate, 309-11 Type 1, 281 erythrocyte sedimentation rate (ESR), likelihood ratios for, 92-3 evidence-based medicine (EBM), 303 cancer screening tests in, 304 - 6cognitive errors in diagnostic process of, 307 clinician, 308-13 differential diagnosis, 308 oversimplification of diagnostic problem, 313 in probability estimates, 308-13 criticisms of, 307 clinical experience denigration as, 304 limits to clinician autonomy as, 306-7 nihilism of, as basis for, 304-6 payment denial as, 306-7 pharmaceutical industry influence as, 307-8 randomized trial overemphasis as, 303-4 statistical expertise overvaluation as, 304 definition of, 2-3 diagnosis in, 2-3 future of, 314-15 as malpractice, 305-6 in media, 304-6 probability in, 308-9 post-test estimate errors in, 311–13 pre-test estimate errors in, 309-11 PSA in, 305-6

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

evidence-based medicine (EBM) (cont.) reasons for teaching, 313-14 treatment in, 2-3 disease classification systems and, 1-2 evolocumab (Repatha[®]), 210, 217, 346-7 excessive screening, reasons for, 254-6 expected agreements, with kappa statistic balanced/unbalanced, 115-16, 333-6 calculations of, 112 definition of, 112-14 marginals impact on, 115 False Discovery Rate (FDR), 288-9 false negative, 8-9 false positive, 8-9 false-negative rate, 12-14 false-negatives, P-values and, 282 - 4false-positive rate, 12-14, 320 - 1false-positives, P-values and, 282 - 4falsification tests, 236-8, 348 FDR. See False Discovery Rate fecal occult blood screening, 269 - 70fetal chromosomal abnormalities, 5, 93-5, 178-83, 186, 188-91 Feynman, Richard, 286-7 fluticasone, randomized trials of, 216-17 focal segmental glomerulosclerosis, 1-2 follow-up loss in randomized trials, 210-11 in risk predictions studies, 161 follow-up time, in observational studies, 241-2, 349 FOURIER trial, 210, 217, 346 - 7Framingham Risk model, decision curves for, 159-60 fremanezumab, for migraine headaches, randomized trials of, 346

trials, 206 gastroenteritis, diagnostic testing for, 318 genetic tests, 162-4 Glasgow Coma Scale, 110-11 weighted kappa statistic for, 120 - 1gold standard test, 8-9 in diagnostic test studies, 76-7, 79-80 differential verification bias and, 81-2, 86-8, 329-30 imperfect gold standard bias and, 81-2, 89-91, 330 - 2incorporation bias and, 78-82, 329 partial verification bias and, 80-5, 330 nonexistent, 91 reliability in lieu of, 110 goodness of fit, in logistic regression, 191-2 green belts, 293-4 Grim Reaper walking speed, 327, 354 group A streptococcus, RADT for, 5, 342-3 Grunderschnauzer disease, dichotomous tests for, 319 Guyatt, Gordon, 2 harms, from screening tests, 252 - 4hazard ratios, 154, 354-5 β -HCG, 4 Health Professionals study, 237, 237 Healy, Bernadine, 304-6 hearing loss, CALFRAST screening for, 327-8 hepatitis C, 330-2 heterogeneous disease, 176 heterogeneous nondisease, 176-7 heuristics, in pre-test probability estimates, 309 - 11hypotheses advance statement of, 286-7 multiple, 287-9 null, 281

funding source, of randomized

ICU Mortality Probability Model, calibration and discrimination in, 153-67 IDI. See integrated discrimination improvement imipramine, for depression, randomized trials with, confidence intervals in, 353 - 4immortal time bias, 242, 349 imperfect gold standard bias, 81-2, 89-91, 330-2 incorporation bias, 78-82, 329 independence, of tests, 175-7 spectrum bias and, 177-8 index testing, in diagnostic test studies, 76-7, 79-80 differential verification bias and, 81-2, 86-8, 329-30 imperfect gold standard bias and, 81-2, 89-91, 330-2 incorporation bias and, 78-82, 329 partial verification bias and, 80-5, 330 individual patient data metaanalysis, 99-100 influenza testing CDC website on rapid, 320-1 prevalence, pre-test probability, post-test probability and accuracy calculations for, 8-14 sensitivity, specificity, positive predictive value and negative predictive value calculations for, 8-11, 320-1 treatment thresholds for, 22-30, 34-6 instrumental variables, 232-5, 244-5, 338-49 integrated discrimination improvement (IDI), 165-6 intentionally ordered tests, 286 intention-to-treat analysis, 211-13, 232-4, 347-8 interaction terms, in logistic regression, 191-2 intermediate test results, spectrum bias from exclusion of, 86-97

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

LRs. See likelihood ratios

lung cancer, screening tests for,

inter-observer agreement, for categorical variables, 111-21, 332-8 inter-rater reliability for diagnosing sexual abuse in prepubertal girls, 336-7 kappa statistic for, 110-12, 333-8 classifications of, 121 for dichotomous variables, 112 - 13expected agreements with, 112-16, 333-6 formula for, 112-15 good, 121 sensitivity and specificity v., 116-17 for three or more categories, 117-21 interval likelihood ratios, 55-9 intervention group, in randomized trials, 207 intuition, anchoring bias and, 311-12 intussusception, differential verification bias in ultrasound of, 86-8 inverse probability of treatment weighting, 239 iron deficiency anemia, 94-5 jaundice, partial verification bias and, 83-5 joint fluid, WBC count in, 322-3 Kahenman, Daniel, 312 kappa statistic, 110-12, 332-3 classifications of, 121 for dichotomous variables, 112-13 expected agreements with balanced/unbalanced, 115-16, 333-6 calculations of, 112 definition of, 112-14 marginals impact on, 115 formula for, 112-15 good, 121 sensitivity and specificity v., 116-17 for three or more categories unweighted, 117 weighted, 117-21

kidney biopsies, 1-2 knee injury, 2 latent phase, of disease, 257 lead time bias, 260-1 leaf, of classification trees, 181-2 length time bias, 261-2 leukemia, classification of, 2 likelihood ratios (LRs), 319-20 definitions of, 16-17 derivation of, 19-20, 32 for ESR, 92-3 interval, 55-9 for multilevel tests, 55-9, 325-6 D-Dimer, 325-6 urine WBC, 323-5 odds ratios v., 187-8 posterior probability calculation with, 16-17, 21 slide rule for, 21-2, 65-6 in testing threshold visualization, 25-7 test independence and, 175 - 7for trisomy 21, 344 for WBC count, 55-9 linear weights, for weighted kappa statistic, 117-19 lipase, serum, 78-80 lipid-lowering agents, perioperative use of, 349 liver biopsy, for hepatitis C staging, 330-2 Local Average Treatment Effect, 234 logarithm of odds, 66 logarithms, 65-6 logistic regression, 185-6 clinical decision rules developed with, 192-5 dichotomous, 186-7 interaction terms and goodness of fit in, 191-2 modeling for, 188-9 odds ratios and, 186-9 for single continuous test, 189 - 90for two continuous tests, 189-91 low back pain, risk predictions for, 152

Kawasaki disease, multiple tests

for, 332-42

k-fold cross validation, 196

350 - 1machine learning, 196-7 MAE. See mean absolute error magnetic resonance imaging (MRI), for multiple sclerosis diagnosis, 99-100 malignant pleural effusion, testing for, 318 malpractice, EBM as, 305-6 mammography, 5, 30, 269-70 in EBM, 304-6 likelihood ratios applied to, 16-17, 21 2×2 table method applied to, 15 - 16Mann-Whitney U-test, 54-5 marginals, 112, 115 masking, in randomized trials, 208-9, 345 MASS. See Multicentre Aneurysm Screening Study Mayo Lung Study, 265 McIsaac Score, for strep throat, 342-3 mean absolute error (MAE), 147-9, 338-9 mean bias, 147-9, 338-9 measurement error, in testing, 110 test-retest reliability and, 125 - 7melanoma, dermoscopy v. naked eye for diagnosing, 332-54 Menger, Fred, 193 Merenstein, Daniel, 305-6 meta-analysis, individual patient data, 99-100 metastatic undifferentiated carcinoma, testing for, 318 migraine headaches, randomized trials for, 346 minimal change disease, 1-2 mortality survival v., 258 total v. cause-specific, 266-8, 267, 269 walking speed as predictor of, 327, 354

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

MRI. See magnetic resonance imaging MS. See multiple sclerosis Multicentre Aneurysm Screening Study (MASS), 350 multilevel tests, 47 CALFRAST screening for hearing loss, 327-8 Grim Reaper walking speed, 327 in hypothetical trial cases, 326-7 likelihood ratios for, 55-9, 325 - 6D-Dimer, 325-6 urine WBC, 323-5 optimal cutoffs for, 61-2 D-Dimer, 325-6 graphical approach to, 63-4 ROC curves and, 62-3 probability for, 59-61 CALFRAST screening, 327-8 D-Dimer, 325 urine WBC, 323-5 multiple hypotheses, multiple tests and, 287-9 multiple sclerosis (MS) genetic tests for, 163-4 systematic review of MRI diagnosis of, 99-100 multiple tests classification trees in, 181-5 decision rules for, 175, 180-1, 192-5 clinician v., 198 k-fold cross validation in, 196 overfitting and, 193-6 test selection for, 192-6 dichotomous logistic regression for, 186-7 result combination of, 178 - 81independence in, 175-7 spectrum bias and, 177-8 for Kawasaki disease, 332-42 logistic regression in, 185-6 clinical decision rules developed with, 192-5 dichotomous, 186-7 interaction terms and goodness of fit in, 191-2 modeling for, 188-9 odds ratios and, 186-9

for single continuous test, 189-90 for two continuous tests, 189-91 machine learning in, 196-7 multiple hypotheses and, 287-9 for pulmonary embolism, 343-4 for strep throat, 342-3 multivariable decision rules, 175, 180-1, 192-5 clinician v., 198 k-fold cross validation in, 196 overfitting and, 193-6 test selection for, 192-6 myocardial infarction classification trees for, 183-4 logistic regression for predicting, 192-3 myocardial ischemia, wall motion abnormalities as test for, 80, 329 nasal bone absence, in Down syndrome diagnosis, 5, 93-5, 178-83, 186, 188-91 National Lung Screening Trial (NLST), 350-1 natural logarithms, 65 NB. See net benefit negative in health (NIH), 9-11 negative predictive value, 8-11, 319-21 in diagnostic test studies differential verification bias effects on, 81-2, 86-8, 329-30 imperfect gold standard bias effects on, 81-2, 89-91, 330-2 incorporation bias effects on, 81-2 partial verification bias effects on, 81-5 spectrum bias effects on, 81-2, 91-3 negative studies, confidence intervals in reporting of, 292 - 3black belt, 295 blue belt, 294 brown belt, 294-5 green belt, 293-4

white belt, 293 vellow belt, 293 neonatal pain, 347-8 nephrotic syndrome, 1-2 net benefit (NB) calculation of, 155-7 decision curves for, 156-60 net reclassification index (NRI), 165-6 new user design, 232-42 newborn bacteremia in, 5, 47-8 confidence intervals in negative studies of, 292 - 5continuous/multilevel testing for, 55-7 posterior probability for multi-level tests of, 60 regret graphs for, 63-4 ROC curve and, 48-51, 55 cooling of, 291-2 jaundice in, partial verification bias and, 83 - 5urinalysis in, ROC curves for, 323 - 5NEXUS Rule, 181 NICE Framingham Risk model, decision curves for, 159-60 NIH. See negative in health NLST. See National Lung Screening Trial NNH. See number needed to harm NNT. See number needed to treat no treat-test threshold, 25-30, 37 - 40nominal variables, 110-11 nonindependence, of tests, 175 - 7spectrum bias and, 177-8 NRI. See net reclassification index nuchal translucency, 178-83, 188-91 null hypothesis, 281 number needed to harm (NNH), in randomized trials, 221-2 number needed to treat (NNT), 3 in randomized trials, 215-18, 220 - 1

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

numeric variables, 110–11 Nurses' Health study, 237

observational studies, 231 confounding by indication in, 231-3 of epidural analgesia and Csection rates, 244-5, 338-47 falsification tests in, 236-8, 348 follow-up time in, 241-2, 349 instrumental variables in, 232-5, 244-5, 338-49 propensity scores in, 238-41, 348-9 of screening tests, 259 lead-time bias in, 260-1 length-time bias in, 261-2 overdiagnosis in, 263-6 stage migration bias in, 261-3, 353 volunteer effect in, 259-60 odds logarithm of, 66 probability and, 16-19, 33 odds ratios confidence intervals for, 293 - 4likelihood ratios v., 187-8 in logistic regression, for multiple tests, 186-9 in randomized trials, 217-18 OME. See otitis media with effusion OncoTypeDX[®], breast cancer staging with, 318-56 ordinal variables, 110-11 continuous, 47 discrete, 47 in randomized trials, 215 oseltamivir (Tamiflu[®]), 218-21 otitis media with effusion (OME), 344-5 Ottawa Ankle Rule, 181 outcome variables, 76-7, 79-80 additional, 236, 348 in randomized trials, 209-10 count, 215 dichotomous, 215-18 in screening tests, 257 ovarian cancer BRCA referral screening tool for, 321-39 screening tests for, 352-3 overconfidence, 312

overfitting in risk predictions studies, 161 in test selection for decision rules, 193-6 oversimplification, in EBM diagnostic errors, 313 pain sensitivity, 347-8 pancreatitis, 78-80 paroxetine, for depression, randomized trials with, confidence intervals in, 353 - 4partial verification bias, 80-5, 330 partitioning, recursive, 181-5 patent ductus arteriosus (PDA), screening for, 348-9 patient information, test information combined with, 14-15 patient populations, alternative, 237-8, 348 payment, EBM in denial of, 306 - 7PCR tests. See polymerase chain reaction tests PDA. See patent ductus arteriosus PE. See pulmonary embolus Pediatric Research in Office Settings (PROS) Febrile Infant Study, 183, 185 Pediatric Ulcerative Colitis Activity Index (PUCAI), reliability of testing for, 334-6 per-protocol analysis, 211-13 pharmaceutical industry, EBM influence by, 307-8 photophobia, as diagnostic test for bacterial meningitis, 330 PID. See positive in disease PLCO Cancer Screening Trial. See Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial plecanatide (Trulance®), 215 pleural effusion, testing for, 318 pneumonia PORT score for, 192-5 risk predictions for, 340

overdiagnosis, 263-6

polymerase chain reaction (PCR) tests, influenza virus, 8-9 pooled cohort equations, in risk predictions for cardiovascular events, 341 - 2PORT Pneumonia Score, 192-5 positive in disease (PID), 9-10 positive predictive value, 8-11, 319-21 in diagnostic test studies differential verification bias effects on, 81-2, 86-8, 329-30 imperfect gold standard bias effects on, 81-2, 89-91, 330-2 incorporation bias effects on, 81-2 partial verification bias effects on, 81-5 spectrum bias effects on, 81-2, 91-3 post Lyme syndrome, randomized trials for, 345 posterior probability, 12-14, 319 in clinical trial analysis, 291 - 2confidence intervals and, 290 EBM diagnostic errors and, 308-9, 311-13 likelihood ratios for calculation of, 16-17, 21 for multilevel tests, 59-61 CALFRAST screening, 327 - 8D-Dimer, 325 urine WBC, 323-5 P-values and, 284, 286 test independence and, 175 - 6 2×2 table method for calculation of, 15-16 post-test probability, 12-14, 308-9. See also posterior probability estimate errors in, 311-13 prediction, 144-6. See also risk predictions predictive value, 8-11, 16 in diagnostic test studies differential verification bias effects on, 81-2, 86-8, 329-30

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

predictive value (cont.) imperfect gold standard bias effects on, 81-2, 89-91, 330-2 incorporation bias effects on, 81-2 partial verification bias effects on, 81-5 spectrum bias effects on, 81-2, 91-3 predictor variables, 76-7, 79-80 additional, 237, 347-8 in screening tests, 257 premature closure, 311 prenatal antidepressants, 354-5 prenatal ultrasound, 5, 93-5, 178-83, 186, 188-91 presymptomatic disease, screening tests for, 251 - 2pre-test probability, 11, 13-14, 308–9. See also prior probability estimate errors in, 309-11 prevalence in dichotomous tests, 9-11 spectrum bias and, 94-5 priming effect, 310-11 prior probability, 11, 13-14 in clinical trial analysis, 291-2 confidence intervals and, 290 diagnostic test study conclusions and, 78 EBM diagnostic errors and, 308 - 11for multilevel tests, 59-61 CALFRAST screening, 327 - 8urine WBC, 323-5 P-values and, 284, 286 test independence and, 175 - 6 2×2 table method for updating, 15-16, 19-20 probability adjustment from anchor in, 310 - 11availability in, 310 conditional, 10 confidence intervals and, 290 diseases and, estimates for, 2-3, 308-13 in EBM, 308-9 post-test estimate errors in, 311-13

pre-test estimate errors in, 309 - 11EBM diagnostic errors and, 308 - 13epistemic, 280-1 likelihood ratios and, 319-20 definitions of, 16-17 derivation of, 19-20, 32 posterior probability calculation with, 16-17, 21 slide rule for, 21-2, 25-7 for multilevel tests, 59-61 CALFRAST screening, 327 - 8D-Dimer, 325 urine WBC, 323-5 odds and, 16-19, 33 posterior (See posterior probability) post-test, 12-14, 308-9 estimate errors in, 311-13 predictive value, 8-11, 16 pre-test, 11, 13-14, 308-9 estimate errors in, 309-11 prior (See prior probability) propensity scores and, 238-41, 349 P-values and, 282, 284, 286 representativeness in, 309 stochastic, 280-1 test independence and, 175 - 6treatment threshold (See treatment threshold probability) 2×2 tables and blank, 15 completed, 16 prevalence, pre-test probability, post-test probability and accuracy, 8-14, 319-20 for prior probability updating, 15-16, 19-20 sampling schemes and, 9-14, 321 sensitivity, specificity, positive predictive value and negative predictive value, 8-11, 319-39 probiotics, for colic, 318 prognostic tests, 144

propensity scores, 238-41, 348-9 PROS Febrile Infant Study. See Pediatric Research in Office Settings Febrile Infant Study Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, 351-3 prostate cancer, 4, 256, 265, 305-6, 351-2 prostate-specific antigen (PSA), 4, 256, 265, 352 in EBM, 305-6 pseudodisease, 263-6 in Mayo Lung Study, 265 P_{TT}. See treatment threshold probability publication bias, 161-2 PUCAI. See Pediatric Ulcerative Colitis Activity Index pulmonary embolus (PE) D-Dimer test for, 60-2, 66, 325-6, 343-4 multiple tests for, 343-4 V/Q scans for, 86-97 Wells Score for, 343-4 P-values, 280 in antidepressant randomized trials, 353 - 4background on classical (frequentist) statistics, 281-2 stochastic and epistemic probability, 280-1 as conditional probability, 2.84 confidence intervals and, 292 - 3black belt, 295 blue belt, 294 brown belt, 294-5 green belt, 293-4 white belt, 293 yellow belt, 293 definition of, 282 diagnostic test analogy with, 282-6 false-positive/false-negative confusion with, 282 - 4hypotheses stated in advance and, 286-7

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

likelihood ratio relationship

intentionally ordered tests and, 286 in multiple hypotheses and multiple tests, 287-9 FDR and, 288-9 QRISK2 score, decision curves for, 159-60 QUADAS. See Quality Assessment of **Diagnostic Accuracy** Studies quadratic weights, for weighted kappa statistic, 119-20 Quality Assessment of Diagnostic Accuracy Studies (QUADAS), 100 - 1QuickVue, sensitivity, specificity, positive predictive value and negative predictive value calculations for, 8 - 11RADT. See rapid antigen detection test random forests[™], 196-7 randomized trials analysis of as-treated, 211-13 bias directions in, 215 intention-to-treat, 211-13, 232-4, 347-8 multiple comparisons in, 214 per-protocol, 211-13 subgroup, 213-14 between v. within-group comparisons in, 214 binding in, 208-9, 345 conduct of, 206-11 confidence intervals, with antidepressants, 353-4 critical appraisal of, 206 design and conduct, 206-11 results analysis, 211-15 design of, 206-11 in diagnostic test studies, 75 - 7equivalency trials and, 215 falsification tests in, 236-8, 348 follow-up losses in, 210-11

follow-up starting point in, 241 FOURIER trial, 210, 217, 346-7 instrumental variables in, 232-5, 244-5, 338-49 outcomes in, 209-10 for post Lyme syndrome, 345 propensity scores and, 238-41, 348-9 purpose of, 205-6 of screening tests, 265-9 treatment effect quantification with, 3, 205 alternatives to, 231-43 CBOP and BBOP, 218-21 continuous, ordinal and count outcome variables in, 215 dichotomous outcome variables in, 215-18 effect size inflation in, with odds ratio, 217-18 for enuresis, 345-6 for migraine headaches, 346 NNH, 221-2 NNT, 215-18, 220-1 for OME, 344-5 relative v. absolute measures of, 216-17 treatment cost per good outcome caused, 221 rapid antigen detection test (RADT), for strep throat, 5, 342-3 rapid influenza diagnostic tests (RIDT), 320-1 rate ratios, 154 recalibration, in risk predictions, 154 receiver operating characteristic (ROC) curve, 51-2 AUROC and, 51, 54-5 for CALFRAST screening, 327 - 8discrimination in risk predictions and, 150-67 for Grim Reaper walking speed, 327 for hypothetical trial cases, 326-7 information in, 55

to, 57-9, 325-6 optimal cutoffs and, 62-3 in signal detection theory, 49-50 SROC, 98-100, 332-54 for urinalysis, 323-5 walking man approach to, 52 - 4for WBC count in joint fluid, 322 - 3WBC counts and, 48-51, 55 Wilcoxon Rank Sum test and, 54-5 recurrence index, for breast cancer, 163 recursive partitioning, 181-5 reference standard. See gold standard test referral bias. See partial verification bias referral screening tool (RST), for BRCA testing, 321-39 regret bias, 310 regret graphs, 23, 63-4 decision curves v., 158-60 relative risk (RR), 215-17 relative risk reduction (RRR), 215-17 reliability, in testing, 110 for AAA, 338 for appendicitis, 333 Bland-Altman plot for, 128-9, 338 modified, 127-30 variable types and, 110 - 11for body packing, 333-8 for chest pain, 333-4 of continuous measurements, 121 average standard deviations and, 123 calibration for, 127-30 correlation coefficients and, 123-5 error by magnitude with, 125 - 7method comparison for, 127 - 9test-retest, 121-9 within-subject standard deviation/repeatability, 122 - 3inter-rater

367

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

reliability, in testing (cont.) for diagnosing sexual abuse in prepubertal girls, 336-7 kappa statistic for, 110-21, 332-8 literature studies of, 130-1 for PUCAI, 334-6 variable types and Bland-Altman plot and, 110 - 11continuous, 110-11 dichotomous, 110-13 discrete, 110-11 kappa statistic and, 110-21, 332-8 nominal, 110-11 numeric, 110-11 ordinal, 47, 110-11 Repatha[®]. See evolocumab repeatability, within-subject standard deviation and, 122 - 3representativeness, in probability estimates, 309 reproducibility. See reliability, in testing research questions, in diagnostic test studies, 79 - 80results diagnostic test, disease probability estimation and, 3 in diagnostic test studies, 76-80 spectrum bias from exclusion of, 86-97 review bias, 78-80 RIDT. See rapid influenza diagnostic tests risk factors, screening tests for, 251 - 2risk predictions, 144 accuracy of calibration in, 147-9, 152-67, 338-9 discrimination in, 146, 150-67, 338-9 NRI and IDI for, 165-6 quantification of, 146–67, 338-9 recalibration and, 154 for cardiovascular events, 341 - 2

for community-acquired pneumonia, 340 for continuous outcomes, 164 diagnostic tests v., 144-6 genetic tests, 162-4 hazard ratios in, 154 rate ratios in, 154 risk ratios in, 154 for stroke after TIA, 339-40 studies of, 160 follow-up loss in, 161 new information quantification in, 162-3 overfitting in, 161 publication bias in, 161-2 treatment effects in, 160-1 value assessment for, 154-5 decision curves, 156-60 net benefit calculations, 155 - 7risk ratios, 154 in randomized trials, 215-17 ROC curve. See receiver operating characteristic curve root, of classification trees, 181 - 2rotavirus testing, for gastroenteritis, 318 RR. See relative risk RRR. See relative risk reduction RST. See referral screening tool Rule of Three, 295-6 salmeterol, randomized trials of, 216-17 sampling schemes for diagnostic test studies, 75 - 7for dichotomous tests, 9-14, 321 screening tests, 250 for AAA, 350 biases in, 258-68 lead-time, 260-1 length-time, 261-2 pseudodisease, 263-6 slippery linkage, 267-8 stage migration, 261-3, 353 sticky diagnosis, 258-68 volunteer effect, 259-60 for cancer differential verification bias in, 86

in EBM, 304-6 overdiagnosis in, 263-5 total v. cause-specific mortality in, 266-9 Cardiac Arrhythmia Suppression Trial, 252 for CHD in Down syndrome, 353 for colon cancer, 269-70 for congenital CMV, 353 critical appraisal of studies of, 257-70 mortality v. survival in, 258 observational studies, 259-66 randomized trials, 265-9 definitions of, 250-1 differential verification bias in. 86 excessive, reasons for, 254-6 false results from, 256 fecal occult blood, 269-70 harms from, 252-4 importance of critical approach to, 252-7 for lung cancer, 350-1 for ovarian cancer, 352-3 for PDA, 348-9 for prostate cancer, 4, 256, 265, 351-2 public support for, 256 randomized trials of, 265-9 types of for presymptomatic disease, 251-2 for risk factors, 251-2 for unrecognized symptomatic disease, 251 - 2underutilization of, 257 SEA. See spinal epidural abscess sensitivity, 8-10, 320-39 in diagnostic test studies, 76 - 80differential verification bias effects on, 81-2, 86-8, 329-30 imperfect gold standard bias effects on, 81-2, 89-91, 330-2 incorporation bias effects on, 81-2, 329 partial verification bias effects on, 81-4, 330

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

spectrum bias effects on,

Index

diagnostic tests, 98-100,

systematic reviews, of

81-2, 91-7, 330 in individual patient data meta-analysis, 99-100 kappa statistic v., 116-17 ROC curves and, 48-51 in systematic reviews, 98-100 sentinel-node biopsy, 356 septic arthritis, 322-3 serum amylase, 78-80 serum lipase, 78-80 severity, disease, 176 sexual abuse in prepubertal girls, reliability of testing for, 336-7 sigmoidoscopy, second outcomes measured for, 236 - 8signal detection theory, 49-50 significance testing, classical (frequentist), 281-2 skin conditions, 2 slide rule, for likelihood ratios, 65 - 6in testing threshold visualization, 25-7 slippery linkage bias, 267-8 small numerators, confidence intervals for, 295-6 SnNOUT mnemonic, 9-10 sonographic screening, prenatal, 5, 93-5, 178-83, 186, 188-91 specificity, 8-11, 320-39 in diagnostic test studies, 76-80 differential verification bias effects on, 81-2, 86-8, 329-30 imperfect gold standard bias effects on, 81-2, 89-91, 330-2 incorporation bias effects on, 81-2, 329 partial verification bias effects on, 81-4, 330 spectrum bias effects on, 81-2, 91-7, 330 in individual patient data meta-analysis, 99-100 kappa statistic v., 116-17 ROC curves and, 48-51 in systematic reviews, 98-100 spectrum bias in bacterial meningitis findings, 330

definition of, 81-2, 91-3 disease definition v., 93-5 disease prevalence and, 94-5 ESR and, 92-3 exclusion of intermediate test results and, 86-97 sensitivity in, 81-2, 91-3 specificity in, 81-2, 91-3 tests nonindependence and, 177 - 8speed bumps, appendicitis diagnosis with, 332 spinal epidural abscess (SEA), accuracy of classic triad for, 319-20 SpPIN mnemonic, 9-11 SROC. See summary receiver operating characteristic curve stage migration bias, 261-3, 353 staging, of breast cancer, 79-80, 318 - 56standard deviation, reliability and average, 123 within-subject, 122-3 statins, peri-operative use of, 349 statistical learning, 196-7 statistical significance testing, 281 - 2stenosis, CTA diagnosis of, 93 sticky diagnosis bias, 258-68 stochastic probability, 280-1 strep throat, 5, 321-2 multiple tests for, 342-3 stroke, risk predictions for, 339-40 study design, for diagnostic test studies, 75-7, 79-80 subarachnoid hemorrhage, 4 subgroup analysis, 213-14 subjects in diagnostic test studies, 75-7, 79-80 in randomized trials, 206-7 in reliability studies, 130-1 summary receiver operating characteristic (SROC) curve, 98-100, 332-54 suppression, 231 surprise question, systematic review of, 98-9 surrogate outcomes, 209 survival, mortality v., 258

332-54 T. See cost of test Tamiflu[®]. See oseltamivir test result-based sampling, 14, 321 test statistics, 282 testing, statistical significance, 281 - 2test-retest reliability, 121 average standard deviation and, 123 correlation coefficient and, 123 - 5error by magnitude with, 125-7 method comparison for, 127-9 within-subject standard deviation/repeatability, 122 - 3tests cancer screening, 86, 263-9 in EBM, 304-6 continuous, 47 dichotomous, 47-8 ROC curves in, 48-55, 57-9, 62-3, 322-6 cost, T, 23 diagnostic (See diagnostic tests) dichotomous (See dichotomous tests) EBM in critical evaluation of, 314 - 15genetic, 162-4 index, 76–7, 79–80 influenza prevalence, pre-test probability, post-test probability and accuracy calculations for, 8-14 sensitivity, specificity, positive predictive value and negative predictive value calculations for, 8-11, 320-1 intentionally ordered, 286 multilevel, 47 likelihood ratios for, 55-9, 323-6 optimal cutoffs for, 61-4, 325-6

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

tests (cont.) probability for, 59-61, 323-5, 327-8 multiple classification trees in, 181 - 5decision rules for, 175, 180-1, 192-6, 198 dichotomous, 178-81, 186 - 7independence in, 175-8 logistic regression in, 185-95 machine learning in, 196-7 multiple hypotheses and, 287 - 9result combination of, 178 - 81prognostic, 144 reliability and measurement error in, 110 screening (See screening tests) test-treat threshold, 25-30, 37 - 403×2 table, for intermediate test results, 86-97 TIA. See transient ischemic attack tolterodine, for enuresis, randomized trials of, 345 - 6total mortality, cause-specific mortality v., 266-9 transient ischemic attack (TIA), risk predictions for, 339-40 treatment, in EBM, 2-3 disease classification systems and, 1-2 treatment cost per good outcome caused, in randomized trials, 221 treatment effects in EBM, 2-3 randomized trials for quantification of, 3, 205 alternatives to, 231-43 CBOP and BBOP, 218-21 continuous, ordinal and count outcome variables in. 215 dichotomous outcome variables in, 215-18 effect size inflation in, with odds ratio, 217-18 for enuresis, 345-6

for migraine headaches, 346 NNH, 221-2 NNT, 215-18, 220-1 for OME, 344-5 relative v. absolute measures of, 216-17 treatment cost per good outcome caused, 221 in risk predictions studies, 160 - 1treatment threshold probability (P_{TT}), 22–40, 321–2 expected cost of, 23-5 formulas for, 34-6 for influenza, 22-30, 34-6 NNT and, 220-1 no treat-test, 25-30, 37-40 testing of for imperfect and costly test, 29-30, 34-6 for imperfect but costless test, 25-6, 29, 34-6 likelihood ratio slide rule in, 25-7 for perfect but risky or expensive test, 28-9, 34 - 6visualization of, 25-7 test-treat, 25-30, 37-40 trial cases, continuous/ multilevel tests and, 326 - 7trisomy 21. See Down syndrome true negative, 8-9 true positive, 8-9 Trulance[®]. See plecanatide 2×2 table prevalence, pre-test probability, post-test probability and accuracy, 8-14, 319-20 sampling schemes and, 9-14, 321 sensitivity, specificity, positive predictive value and negative predictive value, 8-11, 319-39 2×2 table method blank, 15 completed, 16 for updating prior probability, 15-16, 19-20 Tylenol[®]. See acetaminophen Type 1 error, 281

ulcerative colitis, 334-6 ultrasound for AAA reliability of testing for, 338 screening tests, 350 DVT diagnosis with, intermediate test results in, 96-7 for intussusception, differential verification bias in, 86-8 prenatal, 5, 93-5, 178-83, 186, 188–91 unbalanced disagreement, 115-16, 333-6 unrecognized symptomatic disease, screening tests for, 251-2 unweighted kappa statistic, 117 urinalysis (UA), 13-14 ROC curves for, 323-5 urinary tract infection (UTI) odds ratios and likelihood ratios for, 187-8 test nonindependence and spectrum bias in, 177-8 urine culture, 13-14 US Centers for Disease Control (CDC), rapid influenza diagnostic testing web page of, 320-1 US News and World Report, 304-6 US Preventative Health Services Task Force, 256, 304-6, 351-2 UTI. See urinary tract infection vaccination, confidence intervals and, in studies of, 355-6 validation, in test selection for decision rules, 193-6 validation sets, 195-6 variables categorical disease definition and, 93 - 5inter-observer agreement for, 111-21, 332-8 continuous, 110-11 disease definition and, 93, 330

UA. See urinalysis

Cambridge University Press 978-1-108-43671-7 — Evidence-Based Diagnosis 2nd Edition Index <u>More Information</u>

Index

in randomized trials, 215 dichotomous, 110-11 kappa for, 112-13 discrete, 110-11 instrumental, 232-5, 244-5, 338-49 kappa statistic and, 110-21, 332-8 nominal, 110-11 numeric, 110-11 ordinal, 110-11 in randomized trials, 215 outcome, 76-7, 79-80 additional, 236, 348 in randomized trials, 209-10, 215 in screening tests, 257 predictor, 76-7, 79-80 additional, 237, 347-8 in screening tests, 257 verification bias differential, 81-2, 86-8, 329-30 partial, 80-5, 330

viral gastroenteritis, 318 vitamin E, for cardiovascular disease prevention, 231–2, 237 volunteer effect, in screening tests, 259–60 V/Q scans, intermediate test results in, 86–97 walking man approach, to ROC curves, 52–4 walking speed, as mortality predictor, 327, 354 wall motion abnormalities,

with motion ability and the provided and the provided ability of the

white blood cell (WBC) count for appendicitis, 313 for bacteremia, 5, 47-8, 60 in joint fluid, 322-3 likelihood ratios for, 55-9 regret graphs for, 63-4 ROC curve and, 48-51, 55 urine, 323-5 Wilcoxon Rank Sum test, 54-5 within-group comparisons, in randomized trials, 214 within-subject standard deviation, 122-3 work-up bias. See partial verification bias yellow belt, 293 Youden's Index, 51, 165

zero numerators, 295-6